Short answer
CYTOKINETICS INC (CYTK) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $2M (up 318.1% year over year) with net income of −$306M.
Q3 2025 key financials · XBRL
- Revenue
- $2M
- +318.1% YoY · −97.1% QoQ
- Net income
- −$306M
- −90.7% YoY · −127.9% QoQ
- Operating margin
- -8613.4%
- EPS (diluted)
- −$2.55
- −86.1% YoY · −125.7% QoQ
Source: XBRL data from the CYTOKINETICS INC (CYTK) Q3 2025 10-Q on SEC EDGAR. USD.
CYTOKINETICS INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: FDA workforce reductions and government shutdowns may delay NDA approval this quarter, with aficamten PDUFA date extended to Dec 26, 2025
- Updated clinical risk: discontinuation of COURAGE-ALS Phase 3 trial due to futility signals increased uncertainty in drug efficacy demonstration
- Legal/compliance risk: potential FDA-required companion diagnostic for omecamtiv mecarbil depends on third-party Microgenics' success in regulatory clearance and manufacturing
- Near-term operational risk: enrollment challenges in clinical trials caused by competing therapies and patient retention could delay development timelines
- Financial risk: new U.S. tariffs including 10% global baseline and 125% China tariffs may increase raw material costs, impacting contract manufacturing expenses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CYTOKINETICS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.